SEC EDGARMAY 271 min read$JAZZ

McSharry Heather Ann sold $482K of JAZZ

McSharry Heather Ann sold 2,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $241.00 ($0.48M total) on 2026-05-22.

Original reporting

SEC EDGAR · McSharry Heather Ann

Published May 27, 2026, 10:07 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI May 27, 2026, 10:11 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$JAZZ

Neutral

medium confidence

Mentioned

$JAZZ

Relevance

6/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$JAZZNeutralLow

Why it matters

Treat as a sentiment/positioning datapoint rather than a fundamental catalyst; monitor for subsequent insider buys/sales or earnings/guidance changes.

Market read

A single director sale (~$482k) may slightly weigh on sentiment, but without corroborating company news the trading impact should be muted.

What to watch

No 10b5-1 plan is cited; however, Form 4s often reflect non-informational motives, and the article provides no context on prior buying/selling patterns.

Relevance 6/10Timing: Immediate (today’s filing) but expected to have limited follow-through absent additional catalysts.

Background

SEC Form 4 reports insider transactions; this filing documents a director’s open-market sale of Jazz Pharmaceuticals shares.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JAZZNeutralMedium confidence

Context

Jazz Pharmaceuticals director Heather Ann McSharry filed an open-market sale of 2,000 shares at $241/share for ~$482k, disclosed via SEC Form 4.

Expected impact

Likely limited/short-lived impact; any reaction should fade unless follow-on disclosures or fundamentals change.

Evidence & confidence

The filing is a routine director sale (no 10b5-1 plan stated) with modest size relative to typical liquidity; without accompanying company news, directional inference is weak.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector/regulatory catalyst.

Regional

None indicated; disclosure is US SEC EDGAR and does not reference regional operations.

Global

None indicated; no international deal/regulatory event mentioned.

Counterpoint

What could challenge this read

The sale may reflect diversification, tax planning, or scheduled liquidity needs rather than a negative view on Jazz fundamentals.

Key entities

issuer
Jazz Pharmaceuticals plc
Subject of the SEC Form 4 insider transaction disclosure.
director
Heather Ann McSharry
Director who sold 2,000 shares in an open-market transaction.

Read at source ← All news

SEP 23

$JAZZLowAI 8/10

Jazz Pharmaceuticals extends $1.9B in loans to 2033

Jazz Pharmaceuticals extended and repriced its $1.9B loan, pushing the maturity date to 2033 and reducing the interest rate by 50 basis points. The company borrowed an additional $273.3M to refinance existing debt, with the new tranche amortizing over 25 years.

stocktitan.net1 min

SEP 23

$JAZZMed

New Data Highlights the Dosing Flexibility of Low-Sodium Oxybate

Jazz Pharmaceuticals presented data at SLEEP 2026 showing Xywav's dosing flexibility for narcolepsy and idiopathic hypersomnia, with stable regimens achievable in ~42 days. Real-world data indicates 91% use twice-nightly regimens, but clinicians often customize doses. Studies also show cardiovascular benefits of low-sodium oxybate. According to Jazz, Xywav's individualized dosing can improve patient outcomes.

sleepreviewmag.com2 min

SEP 20

$JAZZHighAI 8/10

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals (JAZZ) targets $5B opportunity for zanidatamab, with oncology revenue exceeding $1B. The company expects strong adoption of the triplet regimen and sees limited near-term competition. Jazz also reported 40% growth for Zepzelca and strong early adoption for Modeyso. The company generated $824M cash in H1 and raised $1B through a convertible offering, with plans for further investments and acquisitions.

finance.yahoo.com3 min

SEP 20

$JAZZHighAI 8/10

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals (JAZZ) raised its revenue estimate for Ziihera to $3B-$5B, citing potential expansion in multiple cancer types. The company expects Ziihera to become a first-line standard of care for HER2-positive gastroesophageal adenocarcinoma. Jazz also announced pipeline expansions in epilepsy and sleep-wake disorders, including new clinical trials and formulations.

finance.yahoo.com2 min

SEP 18

$JAZZHighAI 9/10

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

Jazz Pharmaceuticals (JAZZ) acquired Actio Biosciences for $820M, with potential $500M in milestone payments, to gain control of ABS-1230, a treatment for rare childhood epilepsy. Jazz reported Q2 revenue of $1.2B, up 16% YoY, and raised 2026 guidance to $4.6B-$4.75B. The company also acquired Chimerix for $944M in 2025. ABS-1230 is in Phase 1b/2a trials, with early results showing seizure reductions. Jazz trades at ~9.5x forward earnings, offering growth potential but with clinical risks.

fool.com3 min